Chemomab Therapeutics Ltd.CMMB

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Israel · chemomab.com

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high unmet need. Its lead candidate, nebokitug, is a first-in-class dual-activity monoclonal antibody that neutralizes CCL24 and has shown disease-modifying potential across five clinical trials, including the Phase 2 SPRING trial in primary sclerosing cholangitis. In July 2026 it entered a definitive merger agreement with Scipher Medicine Corporation, expected to close before year-end 2026.

Key ratios

ROA

-46.3%TTM

2025 -38.9%2024 -47.1%2023 -48.8%

ROE

-82.2%TTM

2025 -69.5%2024 -91.3%2023 -91.0%

Recent news

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference 2026-08-31 · GlobeNewswire

Track CMMB in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer